RBC Capital lowered the firm’s price target on Intellia Therapeutics (NTLA) to $9 from $14 and keeps a Sector Perform rating on the shares. The company’s Q3 report include the death of the Hy’s Law case patient, which makes it “difficult to see a path forward” for the program and the risk/benefit profile tilts unfavorably, especially for an indication where there are safer therapeutic alternatives, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target lowered to $27 from $33 at Oppenheimer
- Intellia: Patient who experienced Grade 4 liver safety event has passed away
- Intellia Therapeutics reports Q3 EPS (92c) vs. ($1.34) last year
- Intellia Therapeutics price target lowered to $4 from $9 at Baird
- Intellia Therapeutics: Hold Rating Amid Safety Concerns and Regulatory Challenges